Doseology Sciences Inc.
Other OTCTotal Valuation
Doseology Sciences Inc. carries a market capitalization of 1.13M, placing it among publicly traded companies globally. Its enterprise value stands at 2.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.13M |
| Enterprise Value | 2.65M |
Share Statistics
Doseology Sciences Inc. currently has 8.01M shares outstanding.
| Shares Outstanding | 8.01M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 42.74, and the price-to-book ratio stands at 4.02.
| PE Ratio | N/A |
| PS Ratio | 42.74 |
| PB Ratio | 4.02 |
| P/TBV Ratio | 3.42 |
| P/FCF Ratio | -3.38 |
| P/OCF Ratio | -3.38 |
Enterprise Valuation
| EV / Sales | 34.20 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Doseology Sciences Inc. maintains a current ratio of 15.11, meaning it holds 15.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.11 |
| Quick Ratio | 10.52 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -124.77 |
| Return on Assets (ROA) | -69.73 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.84 |
Stock Price Statistics
Doseology Sciences Inc.'s stock has declined approximately -33.43983% over the past 52 weeks. The 50-day moving average sits at 0.41, while the 200-day moving average is 0.61.
| Beta (5Y) | N/A |
| 52-Week Price Change | -33.43983% |
| 50-Day Moving Average | 0.41 |
| 200-Day Moving Average | 0.61 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Doseology Sciences Inc. generated 77,517.00 in revenue and converted that into -828,332.00 in net income, yielding earnings per share of -0.12. EBITDA reached -849,822.00, while operating income came in at -849,822.00.
| Revenue | 77,517.00 |
| Gross Profit | 29,597.00 |
| Operating Income | -849,822.00 |
| Pretax Income | -828,334.00 |
| Net Income | -828,332.00 |
| EBITDA | -849,822.00 |
| EBIT | -849,822.00 |
| Earnings Per Share (EPS) | -0.12 |
Balance Sheet
Total book value stands at 823,835.00, with working capital of 981,137.00 providing operational flexibility.
| Cash & Cash Equivalents | 661,936.00 |
| Total Debt | N/A |
| Net Debt | -661,936.00 |
| Equity (Book Value) | 823,835.00 |
| Book Value Per Share | 0.12 |
| Working Capital | 981,137.00 |
Cash Flow
Doseology Sciences Inc. produced -980,908.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -980,908.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -980,908.00 |
| FCF Per Share | -0.14 |
Margins
Doseology Sciences Inc. operates with a gross margin of 38.18, reflecting its pricing power and cost economics. The operating margin of -1,096.30 and net profit margin of -1,068.58 provide insight into operational efficiency.
| Gross Margin | 38.18 |
| Operating Margin | -1,096.30 |
| Pretax Margin | -1,068.58 |
| Profit Margin | -1,068.58 |
| EBITDA Margin | -1,096.30 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -29.61 |
Stock Splits
Doseology Sciences Inc.'s most recent stock split took place on February 16, 2024 with a 10:1 split ratio.
| Last Split Date | 2/16/2024 |
| Split Ratio | 10:1 |
Scores
Doseology Sciences Inc. posts an Altman Z-Score of 13.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 13.56 |